MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 558768 | Name: A 1120
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A 1120 is a retinol-binding protein 4 (RBP4) antagonist (Ki = 8.3 nM) that can reduce serum RBP4 and retinol, and displaces transthyretin (TTR) from RBP4-TTR complexes.

Chemical Structure

A 1120
A 1120
CAS#1152782-19-8

Theoretical Analysis

MedKoo Cat#: 558768

Name: A 1120

CAS#: 1152782-19-8

Chemical Formula: C20H19F3N2O3

Exact Mass: 392.1348

Molecular Weight: 392.38

Elemental Analysis: C, 61.22; H, 4.88; F, 14.53; N, 7.14; O, 12.23

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
50mg USD 1,550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
A-1120, A1120, 2-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid
IUPAC/Chemical Name
2-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid
InChi Key
MEAQCLPMSVEOQF-UHFFFAOYSA-N
InChi Code
SMILES Code
O=C(NC3=C(C(O)=O)C=CC=C3)N1CCC(C2=C(C(F)(F)F)C=CC=C2)CC1
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 392.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dobri N, Qin Q, Kong J, Yamamoto K, Liu Z, Moiseyev G, Ma JX, Allikmets R, Sparrow JR, Petrukhin K. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):85-95. doi: 10.1167/iovs.12-10050. PMID: 23211825; PMCID: PMC3544424. 2: Vajpai S, Taylor PE, Adholeya A, Leigh Ackland M. Chromium tolerance and accumulation in Aspergillus flavus isolated from tannery effluent. J Basic Microbiol. 2020 Jan;60(1):58-71. doi: 10.1002/jobm.201900389. Epub 2019 Oct 16. PMID: 31617602. 3: Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW Jr, Lam BL. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059. doi: 10.1080/14712598.2018.1513486. Epub 2018 Sep 10. PMID: 30129371. 4: Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1057-1062. doi: 10.1007/s00417-017-3619-8. Epub 2017 Mar 11. PMID: 28285324. 5: Hussain RM, Gregori NZ, Ciulla TA, Lam BL. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin Pharmacother. 2018 Apr;19(5):471-481. doi: 10.1080/14656566.2018.1448060. Epub 2018 Mar 15. PMID: 29542350. 6: Du M, Phelps E, Balangue MJ, Dockins A, Moiseyev G, Shin Y, Kane S, Otalora L, Ma JX, Farjo R, Farjo KM. Transgenic Mice Over-Expressing RBP4 Have RBP4-Dependent and Light-Independent Retinal Degeneration. Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4375–4383. doi: 10.1167/iovs.17-22107. Erratum in: Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4799. PMID: 28813718; PMCID: PMC5560100. 7: Zajc CU, Dobersberger M, Schaffner I, Mlynek G, Pühringer D, Salzer B, Djinović-Carugo K, Steinberger P, De Sousa Linhares A, Yang NJ, Obinger C, Holter W, Traxlmayr MW, Lehner M. A conformation-specific ON-switch for controlling CAR T cells with an orally available drug. Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14926-14935. doi: 10.1073/pnas.1911154117. Epub 2020 Jun 17. PMID: 32554495; PMCID: PMC7334647. 8: Motani A, Wang Z, Conn M, Siegler K, Zhang Y, Liu Q, Johnstone S, Xu H, Thibault S, Wang Y, Fan P, Connors R, Le H, Xu G, Walker N, Shan B, Coward P. Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J Biol Chem. 2009 Mar 20;284(12):7673-80. doi: 10.1074/jbc.M809654200. Epub 2009 Jan 15. PMID: 19147488; PMCID: PMC2658061. 9: Wang Y, Connors R, Fan P, Wang X, Wang Z, Liu J, Kayser F, Medina JC, Johnstone S, Xu H, Thibault S, Walker N, Conn M, Zhang Y, Liu Q, Grillo MP, Motani A, Coward P, Wang Z. Structure-assisted discovery of the first non- retinoid ligands for Retinol-Binding Protein 4. Bioorg Med Chem Lett. 2014 Jul 1;24(13):2885-91. doi: 10.1016/j.bmcl.2014.04.089. Epub 2014 May 2. PMID: 24835984. 10: Miller R, Sanchez-Kazi C. Recurrent urinary tract infection and nephrocalcinosis: Answers. Pediatr Nephrol. 2021 Mar;36(3):553-554. doi: 10.1007/s00467-020-04650-z. Epub 2020 Jun 23. PMID: 32577805. 11: Miller R, Sanchez-Kazi C. Recurrent urinary tract infection and nephrocalcinosis: Questions. Pediatr Nephrol. 2021 Mar;36(3):551-552. doi: 10.1007/s00467-020-04643-y. Epub 2020 Jun 23. PMID: 32577806. 12: Poliakov E, Samuel W, Duncan T, Gutierrez DB, Mata NL, Redmond TM. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1. PLoS One. 2017 Apr 27;12(4):e0176487. doi: 10.1371/journal.pone.0176487. PMID: 28448568; PMCID: PMC5407626. 13: Cioffi CL, Dobri N, Freeman EE, Conlon MP, Chen P, Stafford DG, Schwarz DM, Golden KC, Zhu L, Kitchen DB, Barnes KD, Racz B, Qin Q, Michelotti E, Cywin CL, Martin WH, Pearson PG, Johnson G, Petrukhin K. Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease. J Med Chem. 2014 Sep 25;57(18):7731-57. doi: 10.1021/jm5010013. Epub 2014 Sep 11. PMID: 25210858; PMCID: PMC4174998. 14: Hassler D, Braun R, Kimmig P. Impfungen. Meningokokken [Vaccinations. Meningococci]. Dtsch Med Wochenschr. 2001 Dec 7;126(49):A1120. German. PMID: 11791518. 15: Safi TS, Munday JN. Improving photovoltaic performance through radiative cooling in both terrestrial and extraterrestrial environments. Opt Express. 2015 Sep 21;23(19):A1120-8. doi: 10.1364/OE.23.0A1120. PMID: 26406742. 16: Badaut J, Bix GJ. Vascular neural network phenotypic transformation after traumatic injury: potential role in long-term sequelae. Transl Stroke Res. 2014 Jun;5(3):394-406. doi: 10.1007/s12975-013-0304-z. Epub 2013 Nov 29. PMID: 24323723; PMCID: PMC4028405. 17: Petrukhin K. Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment. Drug Discov Today Ther Strateg. 2013;10(1):e11-e20. doi: 10.1016/j.ddstr.2013.05.004. PMID: 25152755; PMCID: PMC4140438. 18: Aaen GS, Holshouser BA, Sheridan C, Colbert C, McKenney M, Kido D, Ashwal S. Magnetic resonance spectroscopy predicts outcomes for children with nonaccidental trauma. Pediatrics. 2010 Feb;125(2):295-303. doi: 10.1542/peds.2008-3312. PMID: 20123781. 19: Badaut J, Copin JC, Fukuda AM, Gasche Y, Schaller K, da Silva RF. Increase of arginase activity in old apolipoprotein-E deficient mice under Western diet associated with changes in neurovascular unit. J Neuroinflammation. 2012 Jun 18;9:132. doi: 10.1186/1742-2094-9-132. PMID: 22709928; PMCID: PMC3419627. 20: Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18. PMID: 26296295.